Sana Biotechnology, Inc. (SANA) Dividend History

Sana Biotechnology, Inc. focuses on developing regenerative medicine and gene therapy solutions. The company aims to create and deliver engineered cells as medicines for various diseases, utilizing advancements in cell engineering and gene editing technologies to treat conditions with unmet medical needs.

188 East Blaine Street, Suite 400, Seattle, WA, 98102
Phone: (206) 701-7914
Website: https://www.sana.com

Dividend History

Sana Biotechnology, Inc. currently does not pay dividends

Company News

SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Sana Biotechnology, Inc. (SANA) is facing a securities fraud lawsuit alleging the company made false and misleading statements about its financial position and product pipeline, leading to investor losses.

Benzinga
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Sana Biotechnology is facing a securities class action lawsuit alleging the company made false and misleading statements about its financial capacity and the prospects of its product candidates. The lawsuit claims Sana overstated its financial position and was likely to decrease funding or discontinue certain programs.

GlobeNewswire Inc.
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Sana Biotechnology, Inc. (SANA) is facing a securities fraud lawsuit alleging the company made false and misleading statements about its financial position and product pipeline.

Benzinga
Faruqi & Faruqi Reminds Sana Biotechnology Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, Inc. (SANA) for making false and/or misleading statements about its financial capacity and product candidates. The firm reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit against the company.

GlobeNewswire Inc.
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Sana Biotechnology, Inc. (SANA) alleging the company made materially false and misleading statements about its financial capacity, product candidates, and operations.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:49:02 UTC